

KESIMPTA - How does MS develop

[Prescribing information](#)

Image



Image



How does MS develop?

KESIMPTA®▼ (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.¹

For full safety information, please refer to the [KESIMPTA Summary of Product Characteristics \(SmPC\)](#).¹

MS is a complex, autoimmune condition defined by inflammation, demyelination and axonal damage in the CNS. This damage is caused by B-cells within the lymph nodes, which capture auto-antigens from neurons or their myelin sheaths and, upon presentation to T-cells, direct them to attack the body's CNS tissue.^{2,3}

To learn more about the pathogenesis of MS and the role of B-cells in the disease, watch this short video.

Kesimpta®
ofatumumab 20 mg Injection

MS Pathogenesis

Prescribing information can be found at the end of this video.
This video contains promotional content and has been developed and funded by Novartis Pharmaceuticals UK Ltd.
This video is intended for UK healthcare professionals only.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.¹

NOVARTIS

UK | February 2025 | 109623-2

VIDEO

CNS, central nervous system; MS, multiple sclerosis; RMS, relapsing multiple sclerosis.

References:

1. KESIMPTA (ofatumumab) Summary of Product Characteristics.
2. Pender MP, et al. *Curr Allergy Asthma Rep* 2007;(4):285–292.
3. Archelos JJ, et al. *Ann Neurol* 2000;47:694–706.

Image



Safety profile

UK | April 2025 | FA-11381590

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/neuroscience/kesimpta/moa/ms-pathogenesis-video>